Cancer Genetic Testing Market Size, Share & Trends Analysis Report By Type (Cytogenetic Testing/Chromosome Analysis, Biochemical Testing, Molecular Testing, DNA Sequencing), By Application (Lung Cancer, Cervical Cancer, Ovarian Cancer, Prostate Cancer, Breast Cancer, Uterine Cancer), By End-Users (Hospitals and Clinics, Clinical Labs) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Cancer Genetic Testing Market Size

The global cancer genetic testing market size was valued at USD 7.48 billion in 2025 and is projected to grow from USD 8.35 billion in 2026 to USD 20.09 billion by 2034, registering a CAGR of 11.6% during the forecast period from 2026 to 2034. North America dominated the cancer genetic testing market with a market share of 41.7% in 2025.

The rising incidence of breast and lung cancer is the key reason driving the increase of the cancer genetic testing market share over the predicted period.

Cancer genetic testing entails examining an individual's genetic material to detect any alterations or variations that may suggest a susceptibility to specific forms of cancer. Such Testing can aid in evaluating the likelihood of cancer development, directing individualized treatment strategies, and enabling timely identification. The market trends are ascribed to a growing emphasis on R&D of genetic Testing to study the correlation of cancer with the genetic sequence, an increase in hereditary cancer, and an increase in demand for DNA testing kits. However, rigorous regulations around cancer diagnosis may impede market expansion.

Type Insights

The market is further segmented into Cytogenetic Testing/Chromosome Analysis, Biochemical Testing, Molecular Testing, and DNA Sequencing. Molecular Testing commands the maximum share of the market. Molecular Testing refers to a range of techniques that examine the structure and function of nucleic acids, such as DNA and RNA. Molecular-level Testing enables the identification of precise genetic mutations, changes, or anomalies. Polymerase chain reaction (PCR), quantitative PCR (qPCR), and reverse transcription PCR (RT-PCR) are prevalent techniques used in molecular diagnostics. Molecular Testing is crucial in finding genetic markers linked to hereditary disorders, infectious diseases, and cancer. It offers a comprehensive understanding of the genetic material, facilitating accurate diagnostics and tailored treatment strategies.

Biochemical Testing entails the examination of proteins, enzymes, or metabolites to evaluate their levels or activity, yielding insights into possible hereditary abnormalities. Such Testing frequently depends on analyzing blood or urine samples to quantify distinct biomarkers linked to specific medical disorders. Measuring the concentrations of particular enzymes in the blood can be utilized to diagnose metabolic diseases, such as phenylketonuria (PKU). Using biochemical Testing is beneficial for assessing the functional components of the body's biochemistry and detecting any anomalies that could signify underlying hereditary disorders.

Request Customizationto receive a tailored report.

Application Insights

The market can be bifurcated into Lung Cancer, Cervical Cancer, Ovarian Cancer, Prostate Cancer, Breast Cancer, and Uterine Cancer. Breast Cancer generates the highest revenue share in the market. Genetic Testing for breast cancer examines abnormalities in genes like BRCA1 and BRCA2, which greatly enhance the likelihood of developing breast cancer. Additional genetic variables linked to susceptibility to breast cancer may also be assessed. As per the National Breast Cancer Institute, breast cancer is projected to be the prevailing kind of cancer in the United States in 2023, with an approximate anticipation of 300,590 new instances. This accounts for around 30% of all newly diagnosed cases of cancer in females in the year 2023. Detecting genetic abnormalities in breast cancer aids in evaluating risk, allowing for customized screening, preventive measures, and tailored treatment choices for patients with hereditary risk factors.

Lung cancer genetic Testing entails examining distinct congenital abnormalities linked to the formation and advancement of lung malignancies. Typically, mutations in the EGFR gene, which stands for epidermal growth factor receptor, are assessed to inform therapy choices, namely utilizing targeted medicines. Cancer.org predicts that in 2023, around 238,340 individuals will receive a diagnosis of lung cancer, and approximately 127,070 individuals will succumb to the disease. About 20% of lung cancer diagnoses are attributed to those who have never engaged in smoking, and it is projected that around 47,660 non-smokers will receive a lung cancer diagnosis in the year 2023.

Distribution Channels Insights

The market is fragmented into Hospitals, Clinics, and Clinical Labs. Hospitals and Clinics are the major end-users of the market. Genetic testing services are extensively available at hospitals and clinics, where healthcare professionals can request and conduct tests as a component of patient care. Hospitals and clinics play a crucial role in providing individuals with genetic Testing, particularly when these tests are incorporated into broader healthcare services. Genetic Testing at medical facilities is commonly carried out by interdisciplinary teams consisting of genetic counselors, oncologists, and other experts. The genetic test findings in these environments aid in making well-informed decisions about patient treatment plans and risk evaluations. Integrating genetic Testing into hospitals and clinics guarantees a smooth and effortless inclusion of this practice into regular medical care. This promotes cooperation among genetic counselors and other healthcare providers, allowing holistic patient care.

Clinical laboratories are essential in the genetic testing market since they function as specialized facilities with the necessary resources to perform various genetic tests. The laboratories receive samples, conduct tests, and provide comprehensive reports shared with healthcare practitioners and patients. Genetic Testing in clinical laboratories includes applying sophisticated techniques, such as PCR (polymerase chain reaction) and DNA sequencing, to examine genetic material. These laboratories may focus on specific categories of genetic Testing, such as cancer genetic testing or prenatal screening.

Speak to an Analystto discuss market opportunities.

Regional Insights

North America is the most significant global cancer genetic testing market shareholder and is estimated to grow at a CAGR of 11.8% over the forecast period. The United States is anticipated to create more money at the national level. In January 2022, the United States is predicted to have approximately 18.1 million individuals who have survived cancer, accounting for about 5.4% of the total population. Furthermore, it is projected that the number of individuals who have successfully overcome cancer will reach a staggering 22.2 million by the year 2030. The increasing utilization of sophisticated cancer treatment alternatives, combined with the escalating prevalence of cancer, has been a critical factor driving the expansion of the North American market.

• Furthermore, in August 2020, the Dana Farber Cancer Institute established the Center for BRCA and Related Genes to prevent malignancies associated with BRCA mutations. Consequently, the market is expanding due to increased product approvals by the US Food and Drug Administration (FDA), and prominent companies focused on introducing innovative genetic testing products. Various factors, including disease awareness initiatives by the federal government, favorable reimbursement policies, increased demand for improved patient care, advancements in technology, a well-established medical infrastructure, and a growing elderly population, are driving the market growth in the North American region.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia Pacific Cancer Genetic Testing Market Trends

Asia-Pacific is anticipated to exhibit a CAGR of 12.3% over the forecast period. The Asia-Pacific region is projected to experience the most rapid growth during the projection period. The incidence of lung cancer in China has experienced exponential growth. Tobacco smoke exposure is a significant factor contributing to the rising incidence of lung cancer in the country. The Journal of Thoracic Oncology reports that lung cancer comprises 20% of all cancer diagnoses. Consequently, the need for genetic testing services specifically targeting cancer is on the rise in the region.

Moreover, the country's government prioritizes implementing policies to establish systematic cancer prevention and detection programs. As the country's population has grown, the likelihood of individuals being diagnosed with cancer has also risen over time. Moreover, most individuals have demonstrated a propensity for undergoing regular Testing. Consequently, the reliance on genetic testing programs designed explicitly for cancer is growing.

Europe Cancer Genetic Testing Market Trends

Europe's cancer genetic testing industry is undergoing substantial expansion due to breakthroughs in genetic technology, a rise in cancer incidence rates, and a growing awareness of customized medicine. Genetic Testing for different forms of cancer has been widely embraced in the region, leading to enhanced methods for diagnosing, selecting treatments, and assessing risks. The projected number of cancer deaths in the EU-27 for the year 2023 is 1,261,990. There has been a reduction of 6.5% in age-adjusted rates (ASRs) for males and a decrease of 3.7% for women.

Additionally, Europe's Beating Cancer Plan, initiated in 2021, aims to enhance cancer prevention, treatment, and care within the European Union (EU). This plan encompasses European Union activities that specifically target cancer genetics. The research aims to ascertain an individual's genetic susceptibility to cancer development. The initiative additionally seeks to enhance the adoption of two crucial vaccinations that can effectively prevent viral infections that can potentially result in cancer. The immunizations encompass Human papillomaviruses (HPV) and Hepatitis B (HBV).

List of Key and Emerging Players in Cancer Genetic Testing Market